INTRODUCTION

Malignant gastric outlet obstruction (GOO) is a common complication in patients with advanced primary or metastatic malignancies located in the distal gastric or peripancreatic region. Standard treatment options for malignant GOO are duodenal stenting or surgical gastrojejunostomy. Both are effective treatments, but also have their disadvantages: duodenal stenting is minimally invasive, but has a significant risk of re-obstruction requiring reinterventions, while surgical gastrojejunostomy has a better patency, but is invasive and associated with surgery-related morbidity. Endoscopic ultrasonography-guided gastroenterostomy (EUS-GE) using a lumen-apposing metal stent (LAMS) is a novel investigational technique, that seems to overcome the shortcomings of the current standard treatments. It is minimally invasive, and the risk of stent dysfunction due to migration or tumor ingrowth is considered to be low because of the features of the LAMS (bi-flanged, short in length, fully covered, and positioned away from the tumoral area). Here, we report two cases with early LAMS dysfunction after EUS-GE had been performed.

CASE REPORTS

The first case
A 72-year-old male (American Society of Anesthesiologists [ASA] II) presented with symptoms of vomiting and inability to eat since several weeks. Upper endoscopy revealed a large circular gastric carcinoma in the distal antrum, causing an outlet obstruction. Computed tomography (CT) revealed...
loco-regional lymphadenopathy and multiple small bilateral liver metastasis. There were no curative options. Based on the limited extent of metastasis and a reasonable life expectancy of the patient at that time, duodenal stenting was deemed unsuitable due to the risk of re-obstruction over time. As the patient did not prefer undergoing a surgical gastroenterostomy, an EUS-GE was performed to palliate the obstructive symptoms. The direct puncture technique was performed. From the proximal antrum, a 15-mm LAMS (Hot AXIOS ™ Stent and Electrocautery-Enhanced Delivery System; Boston Scientific Co., Marlborough, MA, USA), the standard-diameter LAMS that was used at that moment, was successfully deployed (Fig. 1A). The patient was discharged the next day.

After three weeks, the patient returned with symptoms of early satiety. A second upper endoscopy was performed and it revealed a LAMS obstructed by food impaction (Fig. 1B). The food bolus was extracted endoscopically, and the patient was discharged. Six weeks after the LAMS placement, the patient presented again with recurrent symptoms of GOO. A third upper endoscopy revealed that the LAMS had become stenotic due to hyperplastic tissue overgrowth (Fig. 1C), and the distal flange was buried in the jejunal wall (Fig. 1D). Dilation with a 12-mm controlled radial expansion (CRE)-balloon was performed, but the patient’s symptoms hardly improved. The persisting hyperplastic tissue, covering and obstructing the distal end of the stent, was partly treated by argon plasma coagulation, but a 9.8-mm endoscope still could not pass through the LAMS. The patient was rescheduled for a stent change. The original 15-mm LAMS was removed and replaced by a new 20-mm LAMS (Fig. 1E), ten weeks after the first LAMS placement. Palliative chemotherapy was started four days later. Because of vomiting, upper endoscopies were repeated twice, two days after and one month after initiating the chemotherapy. During both endoscopic examinations, a patent LAMS and an empty stomach were noted. Therefore, the complaints were respectively attributed to chemotherapy (which was discontinued after one cycle, following patient’s wish to stop due to side effects), and to a short and transitory period of food impaction (as the patient was able to eat again spontaneously, after the last upper endoscopy). The patient suffered from a rapidly progressive disease and passed away 4.5 months after the initial LAMS placement.

The second case

A 31-year-old female (ASA I) with a history of melanoma in situ, presented with postprandial nausea and vomiting since 6 weeks. Upper endoscopy revealed external compression of the horizontal part of the duodenum. CT revealed a 55 × 38-
mm mass, originating from the uncinate process, with circular encasement of the proximal superior mesenteric artery and tumor progression in the left para-aortic region. Histological examination confirmed the diagnosis of a locally advanced pancreatic adenocarcinoma. Patient's condition was good, her life expectancy was reasonable, and induction chemotherapy with additional surgery (when tumor regression allowed this) was planned. Therefore, duodenal stenting and surgical gastrojejunostomy were not preferred. Rather, direct EUS-GE was performed, with successful placement of a 20-mm diameter LAMS (Hot AXIOS™ Stent) between the antrum and the small intestine.

Two days later, the patient complained of postprandial epigastric cramps. Upper endoscopy revealed a patent and well-positioned LAMS, which could easily be passed with the pediatric gastroscope. Analgesics were administered for reducing pain, and induction chemotherapy was initiated 16 days after LAMS placement. One day after the first chemotherapy, the patient was readmitted to the hospital because of postprandial vomiting. Upper endoscopy, three weeks after LAMS placement, revealed a patent, but suboptimally expanded LAMS, with the opposite side of the enteral wall blocking the distal end of the LAMS (Fig. 2A). In addition, pressure ulcers were seen at the distal flange of the LAMS (Fig. 2B). As the stent was not fully expanded to its maximal size, the subsequent lengthening of the LAMS was probably the cause of the ulcerations. CRE-balloon dilation up to 20 mm was performed (Fig. 2C), and the patient's symptoms improved. Two months later, however, the 5th chemotherapy cycle had to be postponed because of epigastric pain associated with worsening postprandial nausea and vomiting. A third repeat endoscopy revealed regenerative tissue overgrowth (biopsy proven) obstructing the distal end of the LAMS. Ulcerations were not visible; however, when the LAMS was passed, two small openings were identified (Fig. 2D): one to the jejunum, and a second opening suspected to be a gastro-colonic fistula (since colonic haustrae were identified after exploring the opening with the endoscope). Because the primary tumor regressed after neoadjuvant chemotherapy, a Whipple procedure (pancreaticoduodenectomy) was performed 17 weeks after the LAMS placement. During this procedure, the LAMS was identified, positioned in the stomach and attached to the transverse co-

Fig. 2. The second case. (A) Relative stenosis of the lumen-apposing metal stent—before dilation. (B) Jejunal pressure ulcers (arrows). (C) Balloon dilation of relative stenosis—after dilation. (D) Gastro-colonic fistula (left arrow) and jejunum (right arrow). (E) Surgical specimen of the transverse colon and jejunum with lumen-apposing metal stent in situ.
ion and to a jejunal loop. A right hemicolecction, combined with a partial jejunal resection and resection of the greater curvature of the stomach, was performed to remove both the LAMS and the fistula. The surgical specimen of the resected LAMS showed the LAMS with tissues of the transverse colon and jejunum (Fig. 2E). Further pathological evaluation of the jejunum revealed the presence of gastric mucosa and ulcerations. Tissue around the stent (colon, jejunum, and distal stomach) was tumor-free. The patient experienced a complicated recovery, and was discharged after two months. Because of R1 tumor resection, adjuvant chemotherapy was indicated; however, the patients’ physical condition did not allow this. Seven months after the LAMS placement (four months after surgery), the patient developed an ileus of the small intestine and was diagnosed with peritoneal carcinomatosis. She was discharged home with best supportive care.

DISCUSSION

Long-term patency of EUS-GE is crucial to maintain oral intake, avoid hospital admissions, and improve quality of life in patients with malignant GOO. Some of the currently available studies did not report any case of stent dysfunction. Other studies reported one or two cases of stent dysfunction, either due to food impaction, inflammatory tissue overgrowth, mesh erosion, or stent ingrowth. Two case reports described tissue ingrowth of a 15-mm LAMS after more than six months, due to mesh erosion or failure of stent covering. Yet, the timing of stent dysfunction was not always reported. In the present cases, patency was compromised early after the LAMS placement and with intact LAMS covering, requiring multiple repeat endoscopies.

The distal flange that was buried within the layers of the jejunal wall due to hyperplastic tissue overgrowth, as seen in the first case, occurred six weeks after the initial stent placement. A comparable case has been described recently, though it concerned the gastric flange of the LAMS and occurred after an indwelling time of 13 months. It resembles the so-called buried bumper syndrome, a known complication of (semi-) rigid fixation devices, that presents with hyperplastic tissue growth over the edge. Likewise, in patients with pancreatic fluid collections (PFC) treated with EUS-guided drainage using LAMS, buried stent syndrome has been reported, in particular after an indwelling time of more than 4 weeks. In the second case of the present study, hyperplastic tissue overgrowth occurred after seven weeks. Here, it concerned a 20-mm LAMS. The larger diameter of the stent apparently did not protect it from obstruction.

The relative LAMS stenosis with jejunal ulceration occurred three weeks after initial LAMS placement. It could be explained by the narrowing and subsequent lengthening of the stent, causing pressure ulcerations. Ulceration at the LAMS site has been reported previously. Some authors therefore suggested regular evaluation of the LAMS after EUS-GE, either by CT-scan or repeated endoscopies, to reduce the incidence of adverse events such as tissue overgrowth and ulcerations.

The gastro-colonic fistula, which occurred 11 weeks after the LAMS placement, might have resulted from suboptimal deployment and subsequent lengthening of the stent, causing prolonged pressure erosions due to friction between the transverse colon and the flanges of the gastro-jejunal LAMS. The mechanism might be similar to when LAMS is impinging adjacent vasculature causing friction and bleeding, when used for draining PFC. Another explanation could be that the colon was too close to the jejunum during the stent placement, and might have already been intertwined and connected to the LAMS at that stage, resulting in pressure necrosis and gradual fistulization.

In conclusion, EUS-GE stent dysfunction rates reported in literature are low. We reported two cases of early LAMS dysfunction complicating EUS-GE in patients with malignant GOO, compromising patency and causing substantial morbidity. Although EUS-GE has the potential of being a minimally invasive and durable treatment for malignant GOO, there is insufficient evidence to endorse EUS-GE as standard of care for GOO. To date, numbers and causes of LAMS dysfunction have not been clearly evaluated and elucidated, respectively. Therefore, it is important to be aware that (early) recurrent symptoms and adverse events can occur. Prospective studies with adequate follow-up and registration of adverse events are crucial to evaluate the effectiveness and safety of novel techniques such as EUS-GE.

Conflicts of Interest

Leon M. G. Moons and Frank P. Vleggaar are consultants for Boston Scientific Corporation. The other authors have no financial conflicts of interest.

Author Contributions

Conceptualization: Alderina Bijlsma, Leon M. G. Moons, Matthijs P. Schwartz, Frank P. Vleggaar
Data curation: Janine B. Kastelijn, Veronique Van der Voort
Supervision: AB, LMGM, MPS, FPV
Writing-original draft: JBK, VVV
Writing-review & editing: JBK, VVV, AB, LMGM, MPS, FPV

ORCID

Janine B. Kastelijn: https://orcid.org/0000-0003-1298-3561
Veronique Van der Voort: https://orcid.org/0000-0003-3163-5941
Alderina Bijlsma: https://orcid.org/0000-0002-8512-9174
Leon M. G. Moons: https://orcid.org/0000-0002-6913-9954
Matthijs P. Schwartz: https://orcid.org/0000-0003-3106-3373
REFERENCES